Your browser doesn't support javascript.
loading
Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
Blum, Kenneth; Baron, David; McLaughlin, Thomas; Thanos, Panayotis K; Dennen, Catherine; Ceccanti, Mauro; Braverman, Eric R; Sharafshah, Alireza; Lewandrowski, Kai-Uwe; Giordano, John; Badgaiyan, Rajendra D.
Afiliação
  • Blum K; Center for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA.
  • Baron D; The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
  • McLaughlin T; Center for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA.
  • Thanos PK; The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
  • Dennen C; Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York, Buffalo, NY, USA.
  • Ceccanti M; Department of Family Medicine, Jefferson University School of Medicine, Philadelphia, PA, USA.
  • Braverman ER; Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Sharafshah A; The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
  • Lewandrowski KU; Division of Genetics, Department of Cell and Molecular Biology and Microbiology, School of Science and Biotechnology, University of Isfahan, Isfahan, Iran.
  • Giordano J; Department of Orthopaedics, Fundación Universitaria Sanitas Bogotá D.C. Colombia.
  • Badgaiyan RD; The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
J Addict Psychiatry ; 8(1): 1-33, 2024 Apr 05.
Article em En | MEDLINE | ID: mdl-38765881
ABSTRACT
Annotated bibliography of genetic addiction risk severity (GARS) publications, pro-dopamine regulation in nutraceuticals (KB220 nutraceutical variants), and policy documents. Further research is required to encourage the field to consider "Reward Deficiency Syndrome (RDS) Anti-addiction Modeling" which involves early risk identification by means of genetic assessment similar to GARS, followed by induction of dopamine homeostasis by means of genetically guided pro-dopamine regulation similar to KB220. These results suggest that genetically based treatments may be a missing piece in the treatment of substance use disorder (SUD).
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article